ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enliven Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$38.70+1.38 (+3.70%)
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$17.29 (+80.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.56B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.86
- Dividend yield
- –
- Free cash flow yield
- -2.62%
Fundamentals
- Net income
- -$105.93M
- EPS, diluted
- -$1.67
- Free cash flow
- -$67.04M
- Book value per share
- $13.53
- Diluted shares
- 66M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$124.41M
Net income
-$105.93M
EPS, diluted
-$1.67
Free cash flow
-$67.04M
Reported periodTrailing twelve months